Literature DB >> 19265350

Bone pain due to fractures revealing osteomalacia related to tenofovir-induced proximal renal tubular dysfunction in a human immunodeficiency virus-infected patient.

Serge Perrot1, Elisabeth Aslangul, Tali Szwebel, Nadine Caillat-Vigneron, Claire Le Jeunne.   

Abstract

Tenofovir is a nucleoside reverse transcription inhibitor used to treat human immunodeficiency virus patients with early treatment failure. Increasing numbers of cases of tubular dysfunction and Fanconi syndrome have been reported in patients treated with tenofovir, after the detection of biochemical abnormalities during routine assessments. Some patients have acute renal failure, and bone involvement is observed in rare cases. We describe a case of chronic metabolic complications with bone fractures related to tenofovir treatment. Several factors that increased the renal toxicity of tenofovir included low body mass index, concomitant use of nonsteroidal anti-inflammatory agents, and other antiretroviral drugs, including ritonavir.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19265350     DOI: 10.1097/RHU.0b013e31819c20d8

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  24 in total

Review 1.  Antiretroviral therapy: current drugs.

Authors:  Alice K Pau; Jomy M George
Journal:  Infect Dis Clin North Am       Date:  2014-09       Impact factor: 5.982

2.  Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B.

Authors:  Andrés Duarte-Rojo; E Jenny Heathcote
Journal:  Therap Adv Gastroenterol       Date:  2010-03       Impact factor: 4.409

Review 3.  Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?

Authors:  Jérôme Tourret; Gilbert Deray; Corinne Isnard-Bagnis
Journal:  J Am Soc Nephrol       Date:  2013-09-19       Impact factor: 10.121

4.  Long-term treatment with tenofovir in Asian-American chronic hepatitis B patients is associated with abnormal renal phosphate handling.

Authors:  Connie Tien; Jason J Xu; Linda S Chan; Mimi Chang; Carolina Lim; Sue Lee; Brian Huh; Shuntaro Shinada; Ho S Bae; Tse-Ling Fong
Journal:  Dig Dis Sci       Date:  2014-09-20       Impact factor: 3.199

5.  Hypophosphatemic osteomalacia induced by tenofovir in HIV-infected patients.

Authors:  Lourdes Mateo; Susana Holgado; Maria Luisa Mariñoso; Ricard Pérez-Andrés; Anna Bonjoch; Joan Romeu; Alejandro Olivé
Journal:  Clin Rheumatol       Date:  2014-05-03       Impact factor: 2.980

6.  Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens.

Authors:  Todd T Brown; Allison C Ross; Norma Storer; Danielle Labbato; Grace A McComsey
Journal:  Antivir Ther       Date:  2011

7.  Recent developments in HIV-related kidney disease.

Authors:  Michelle M Estrella; Derek M Fine; Mohamed G Atta
Journal:  HIV Ther       Date:  2010-09

8.  Bilateral sub-trochanteric femur fragility fractures in a patient on antiretroviral therapy: a case based discussion and review of literature.

Authors:  Rajesh K Rajnish; Pratik M Rathod; Sameer Aggarwal; Saurabh Agarwal; Prasoon Kumar
Journal:  Int J Burns Trauma       Date:  2020-08-15

Review 9.  Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention.

Authors:  Kenneth K Mugwanya; Jared M Baeten
Journal:  Expert Opin Drug Saf       Date:  2015-12-23       Impact factor: 4.250

10.  Tenofovir-associated bone density loss.

Authors:  Iwen F Grigsby; Lan Pham; Louis M Mansky; Raj Gopalakrishnan; Kim C Mansky
Journal:  Ther Clin Risk Manag       Date:  2010-02-02       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.